Inactive Instrument
Pluristem Therapeutics Inc. Stock Nasdaq
Stocks
US72940R1023
Biotechnology & Medical Research
| Market Cap | 12.78M 11.35M 10.63M 9.63M 18.15M 1.23B 18.3M 128M 49.61M 628M 47.96M 46.93M 2.02B | P/E 2025 |
-1.39x | P/E 2026 | -0.85x |
|---|---|---|---|---|---|
| Enterprise Value | 39.89M 35.42M 33.18M 30.05M 56.67M 3.84B 57.13M 398M 155M 1.96B 150M 146M 6.31B | EV / Sales 2025 |
39,078,124x | EV / Sales 2026 | 48,878,101x |
| Free-Float |
57.48% | Yield 2025 * |
-
| Yield 2026 | - |
| 1 day | +11.70% |
| Manager | Title | Age | Since |
|---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 54 | 2017-03-28 |
Liat Zalts
DFI | Director of Finance/CFO | 42 | 2022-11-30 |
Ori Shalem
COO | Chief Operating Officer | - | 2024-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Yaky Yanay
BRD | Director/Board Member | 54 | 2015-01-31 |
| Director/Board Member | 56 | 2021-01-05 | |
| Director/Board Member | 64 | 2021-05-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +11.70% | -24.18% | - | - | 12.78M | ||
| +4.16% | +3.42% | +49.37% | +94.17% | 74.31B | ||
| +2.76% | -1.16% | +23.05% | +83.03% | 56.95B | ||
| +0.24% | -1.37% | +4.08% | +37.22% | 48.3B | ||
| -3.76% | -0.93% | +327.90% | +691.25% | 44.51B | ||
| -2.30% | -4.06% | +25.82% | +31.42% | 43.8B | ||
| +0.31% | -1.15% | +5.50% | +112.56% | 41.12B | ||
| -0.11% | +2.30% | +9.19% | +58.68% | 31.07B | ||
| +4.51% | +8.43% | +37.27% | +34.97% | 28.97B | ||
| -1.96% | -3.38% | -9.25% | -12.85% | 24.53B | ||
| Average | +1.55% | -0.20% | +52.55% | +125.61% | 43.73B | |
| Weighted average by Cap. | +0.77% | -0.50% | +56.58% | +134.21% |
| 2025 | 2026 | |
|---|---|---|
| Net sales | 1.34 1.19 1.11 1.01 1.9 128.74 1.91 13.34 5.19 65.66 5.01 4.91 211.3 | 1.02 0.9 0.85 0.77 1.44 97.9 1.46 10.15 3.94 49.94 3.81 3.73 160.69 |
| Net income | -22.58M -20.06M -18.79M -17.01M -32.09M -2.18B -32.34M -226M -87.69M -1.11B -84.76M -82.94M -3.57B | -23.82M -21.16M -19.82M -17.95M -33.84M -2.3B -34.12M -238M -92.49M -1.17B -89.41M -87.49M -3.77B |
| Net Debt | 13.44M 11.93M 11.18M 10.12M 19.09M 1.29B 19.24M 134M 52.17M 660M 50.43M 49.35M 2.13B | 27.11M 24.08M 22.55M 20.42M 38.52M 2.61B 38.83M 271M 105M 1.33B 102M 99.57M 4.29B |
Employees
-
















